142 related articles for article (PubMed ID: 25961323)
21. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies.
Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250
[TBL] [Abstract][Full Text] [Related]
22. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
[TBL] [Abstract][Full Text] [Related]
23. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
24. Structure of human protein kinase CK2 alpha 2 with a potent indazole-derivative inhibitor.
Nakaniwa T; Kinoshita T; Sekiguchi Y; Tada T; Nakanishi I; Kitaura K; Suzuki Y; Ohno H; Hirasawa A; Tsujimoto G
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Feb; 65(Pt 2):75-9. PubMed ID: 19193990
[TBL] [Abstract][Full Text] [Related]
25. A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase.
Kinoshita T; Sekiguchi Y; Fukada H; Nakaniwa T; Tada T; Nakamura S; Kitaura K; Ohno H; Suzuki Y; Hirasawa A; Nakanishi I; Tsujimoto G
Mol Cell Biochem; 2011 Oct; 356(1-2):97-105. PubMed ID: 21735094
[TBL] [Abstract][Full Text] [Related]
26. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.
Laudet B; Barette C; Dulery V; Renaudet O; Dumy P; Metz A; Prudent R; Deshiere A; Dideberg O; Filhol O; Cochet C
Biochem J; 2007 Dec; 408(3):363-73. PubMed ID: 17714077
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin.
Cozza G; Zonta F; Dalle Vedove A; Venerando A; Dall'Acqua S; Battistutta R; Ruzzene M; Lolli G
FEBS J; 2020 May; 287(9):1850-1864. PubMed ID: 31661600
[TBL] [Abstract][Full Text] [Related]
28. Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor.
Niefind K; Bischoff N; Golub AG; Bdzhola VG; Balanda AO; Prykhod'ko AO; Yarmoluk SM
Pharmaceuticals (Basel); 2017 Jan; 10(1):. PubMed ID: 28085026
[TBL] [Abstract][Full Text] [Related]
29. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
31. Semiempirical quantum mechanical method PM6-DH2X describes the geometry and energetics of CK2-inhibitor complexes involving halogen bonds well, while the empirical potential fails.
Dobes P; Rezác J; Fanfrlík J; Otyepka M; Hobza P
J Phys Chem B; 2011 Jul; 115(26):8581-9. PubMed ID: 21648479
[TBL] [Abstract][Full Text] [Related]
32. Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'.
Hochscherf J; Lindenblatt D; Witulski B; Birus R; Aichele D; Marminon C; Bouaziz Z; Le Borgne M; Jose J; Niefind K
Pharmaceuticals (Basel); 2017 Dec; 10(4):. PubMed ID: 29236079
[TBL] [Abstract][Full Text] [Related]
33. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
Bollacke A; Nienberg C; Borgne ML; Jose J
J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
[TBL] [Abstract][Full Text] [Related]
34. Primary and secondary interactions between CK2alpha and CK2beta lead to ring-like structures in the crystals of the CK2 holoenzyme.
Niefind K; Issinger OG
Mol Cell Biochem; 2005 Jun; 274(1-2):3-14. PubMed ID: 16335523
[TBL] [Abstract][Full Text] [Related]
35. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
36. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
37. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit.
Ermakova I; Boldyreff B; Issinger OG; Niefind K
J Mol Biol; 2003 Jul; 330(5):925-34. PubMed ID: 12860116
[TBL] [Abstract][Full Text] [Related]
39. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
40. Thermodynamics parameters for binding of halogenated benzotriazole inhibitors of human protein kinase CK2α.
Winiewska M; Kucińska K; Makowska M; Poznański J; Shugar D
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1708-17. PubMed ID: 25891901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
